Researcher Spotlight: Benedikt Pelzer, MD WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY The Levine Family Fellowship Marginal zone lymphoma (MZL) is a slow-growing type of cancer that can eventually transform into a more aggressive diffuse B-cell lymphoma (DLBCL) in a subset…
Researcher Spotlight: Atish Kizhakeyil, PhD UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER Alterations in the DTX1 gene are highly prevalent in diffuse large B-cell lymphoma (DLBCL), but their clinical significance remains unclear. Using animal models and advanced genomic technologies, Dr.…
Researcher Spotlight: Alberto Carturan, MD UNIVERSITY OF PENNSYLVANIA Jaime Peykoff Follicular Lymphoma Fellow Chimeric antigen receptor (CAR) T-cell therapies represent a groundbreaking advancement in the treatment of lymphoma. While CAR T-cell therapies have produced remarkable results for many patients, these…
Researcher Spotlight: Gonzalo Blanco Ares, PhD THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH Bruce D. Cheson, MD Fellow Care of patients with chronic lymphocytic leukemia (CLL) is complicated by the immunodeficiency that is associated with the disease, which can lead to…
Researcher Spotlight: Ruth Alonso-Alonso, PhD THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK Oliver W. Press, MD, PhD Memorial Fellow Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive form of peripheral T-cell lymphoma. Therapeutic options for AITL are…
Researcher Spotlight: Samuel Yamshon, MD WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY The lymphoma treatment landscape has been dramatically changed in recent years with the development of novel immunotherapies such as chimeric antigen receptor (CAR) T cells and bispecific antibodies. Dr.…
Researcher Spotlight: Yucai Wang, MD MAYO CLINIC ROCHESTER Dr. Wang’s interest in cancer research began during his time in medical school at Nanjing University in China. He had lost two close family members to lymphoma and was drawn to pursue…
Researcher Spotlight: Timothy Vorhees, MD THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE Post-transplant lymphoproliferative disorders (PTLDs) are aggressive forms of lymphoma that develop after a solid organ transplant, often due to reactivation of the Epstein-Barr virus (EBV) following the use…
Researcher Spotlight: Harsh Shah, DO The University of Utah Immunotherapy with checkpoint inhibitors is commonly used for treatment of Hodgkin lymphoma after relapse. While many patients initially respond to these therapies, the development of resistance is common over time. Dr.…
Researcher Spotlight: Christine Ryan, MD Dana-Farber Cancer Institute Upfront treatment of mantle cell lymphoma (MCL) typically involves an aggressive approach to treatment that offers the best chance of a durable and lasting response. Dr. Ryan is investigating a new first-line…